A pilot trial of therapeutic vaccination with a modified gp100 melanoma peptide (gp100:209-217(210M)) [melanoma vaccine gp100], montanide ISA 51, and KLH [keyhole limpet haemocyanin] with reconstitution after chemotherapy to induce lymphopenia in patients with metastatic melanoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Melanoma vaccine gp100 (Primary) ; Fludarabine; Keyhole limpet haemocyanin; Montanide ISA-51
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 04 Apr 2013 Biomarkers information updated
- 30 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 30 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.